Sarkar Subham, Ghosh Soubhagya, Chakraborty Samraggi, Rajak Jenifer, Chowdhury Ekanansha R, Mitra Arup K, Kumer Ajoy, Dhara Bikram
Postgraduate and Research Department of Biotechnology St. Xavier's College (Autonomous) Kolkata India.
Postgraduate and Research Department of Microbiology St. Xavier's College (Autonomous) Kolkata India.
Health Sci Rep. 2024 Oct 28;7(11):e70147. doi: 10.1002/hsr2.70147. eCollection 2024 Nov.
Cancer therapy is one of the most researched upon medical field in the world. Non invasive technologies such as liquid biopsy are gaining more importance in cancer therapy because of their manifold advantages over traditional invasive biopsy methods. Liquid biopsy is used to analyze nucleic acids such as ctDNA, cfDNA and RNA, cellular and subcellular components such as proteins, extracellular vesicles and circulating tumor cells in various biological fluids such as blood, urine, cerebrospinal fluid, pleural fluid and ascites fluid for diagnosis of cancer.
Liquid biopsy has a wide range of applications such as assessment of residual diseases and tumors which cannot be biopsied easily and prediction of CAR-T response and response to immune checkpoint inhibitors. It can also be used to know the efficacy of cancer drugs in a patient by analyzing multiple samples. Liquid biopsy is becoming more popular as it allows biopsy of those samples in which solid tumor biopsies are challenging or impracticable.
To achieve comprehensive insight on the status of cancer in a patient, various cutting edge liquid biopsy techniques have been developed. Microfluidics and photonic technologies, along with PCR, next generation sequencing, advanced and innovative molecular and cell biology approaches and imaging techniques have expanded the domain of liquid biopsy and elevated the accuracy of liquid biopsy results.
This review discusses about the contributions of some widely used methods along with microfluidics and photonic technologies in detection of cancer biomarkers by liquid biopsy.
癌症治疗是世界上研究最多的医学领域之一。液体活检等非侵入性技术在癌症治疗中越来越重要,因为它们相对于传统侵入性活检方法具有多种优势。液体活检用于分析血液、尿液、脑脊液、胸水和腹水等各种生物体液中的核酸,如循环肿瘤DNA(ctDNA)、游离DNA(cfDNA)和RNA;细胞及亚细胞成分,如蛋白质、细胞外囊泡和循环肿瘤细胞,以用于癌症诊断。
液体活检有广泛的应用,如评估难以进行活检的残留疾病和肿瘤,预测嵌合抗原受体T细胞(CAR-T)反应及对免疫检查点抑制剂的反应。通过分析多个样本,它还可用于了解患者体内癌症药物的疗效。液体活检越来越受欢迎,因为它能对那些难以或无法进行实体瘤活检的样本进行活检。
为全面了解患者的癌症状况,已开发出各种前沿的液体活检技术。微流控技术、光子技术,以及聚合酶链反应(PCR)、下一代测序、先进创新的分子与细胞生物学方法和成像技术,扩展了液体活检的领域,提高了液体活检结果的准确性。
本综述讨论了一些广泛使用的方法以及微流控技术和光子技术在通过液体活检检测癌症生物标志物方面的贡献。